There's a reason racehorses have been given Thymosin Beta-4 for decades. Before biohackers ever got hold of it, performance veterinarians were already injecting it into elite horses recovering from soft tissue injuries — because it worked. TB-500, the synthetic fragment of Thymosin Beta-4 that humans use, has quietly become one of the most respected recovery compounds in serious athletic and longevity circles.
This is not a supplement in any traditional sense. It's a signaling peptide — a short chain of amino acids that tells your body to shift into an accelerated healing mode. When you understand what it's actually doing at the cellular level, the results people report stop being surprising.
Here's the complete picture, both for people who just want to know if it's worth trying, and for those who want to understand the biology.
For BeginnersTB-500 is a synthetic version of a naturally occurring protein fragment called Thymosin Beta-4. Your body already makes Thymosin Beta-4 — it's found in high concentrations in wound healing tissue, platelets, and in blood plasma after injury. Scientists isolated the most biologically active portion of this protein and synthesized it as a research peptide. That fragment is TB-500.
The core function of Thymosin Beta-4 in your body is regulating actin — a structural protein that makes up a huge portion of your cells' scaffolding. Actin is involved in how cells migrate, divide, and organize themselves after an injury. When tissue gets damaged, your body needs cells to move toward the injury site and rebuild. Thymosin Beta-4 (and by extension TB-500) is a master regulator of that process.
TB-500 is particularly valuable for people dealing with chronic overuse injuries — the kind that never fully heal with rest alone. The combination of actin regulation and anti-inflammatory signaling addresses the root problem rather than masking symptoms.
Three groups see the most benefit from TB-500:
Thymosin Beta-4's primary biochemical function is sequestering G-actin (globular actin monomers), keeping them in a soluble pool ready for rapid polymerization when needed. The active fragment in TB-500 — the amino acid sequence LKKTETQ (positions 17-23 of the full protein) — is the actin-binding domain responsible for this activity. By maintaining a mobile pool of actin monomers and facilitating rapid filament formation in response to cellular signals, TB-500 enables faster, more coordinated cellular migration to injury sites.
TB-500 downregulates pro-inflammatory cytokines including TNF-alpha and IL-1beta while upregulating anti-inflammatory interleukins in a tissue-specific manner. Critically, this is not a blanket immunosuppressive effect — it modulates the resolution phase of inflammation rather than blocking the initial acute response, which is necessary for proper healing. This nuance makes TB-500 meaningfully different from anti-inflammatory drugs, which often blunt the acute phase and paradoxically impair healing outcomes.
Thymosin Beta-4 upregulates several angiogenic factors including HIF-1alpha and VEGF in ischemic tissue, stimulating neovascularization. In cardiac models, systemic or local TB-4 administration post-infarction has promoted cardiomyocyte survival, epicardial progenitor cell activation, and functional recovery. While these cardiac effects are currently research-stage, they underscore the peptide's systemic reach beyond the musculoskeletal applications it's known for in athletic contexts.
Vladimir Khavinson's work at the St. Petersburg Institute of Bioregulation identified a class of short peptides derived from the thymus gland — including Thymogen and Thymulin — that regulate immune function, cellular aging, and tissue repair. TB-500's relationship to thymic biology runs deeper than its name suggests: Thymosin Beta-4 was originally identified in thymic tissue and plays a role in T-cell development and immune priming. Khavinson's research demonstrated that thymus-derived peptides could restore immune function in aged organisms, reduce cellular markers of aging, and extend healthy lifespan in animal models. This connects to a broader principle in Khavinson's framework: short regulatory peptides from specific organs restore the gene expression patterns of younger tissue. TB-500 sits within this paradigm — a thymic peptide fragment that may carry restorative epigenetic signaling beyond its immediate anti-inflammatory applications.
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Loading (acute injury) | 2–2.5 mg | 2x per week | 4–6 weeks |
| Maintenance | 2–2.5 mg | 1x per week | 4–6 weeks |
| Longevity / preventive | 2 mg | 1x per week or biweekly | Ongoing cycles |
Administration is subcutaneous injection, typically into the abdomen. Because TB-500's mechanism is systemic (unlike BPC-157, which can be injected near the injury site), injection location near the target tissue is less critical — systemic distribution is the primary mechanism.
The BPC-157 + TB-500 combination is the gold standard injury-recovery stack. The mechanistic complementarity is precise: BPC-157 drives local angiogenesis and GH receptor upregulation at the injury site, while TB-500 handles systemic cellular migration, actin dynamics, and inflammatory resolution. They operate on non-overlapping pathways, which is why the stack produces effects greater than either compound alone. Standard protocol runs both during the loading phase, then decides continuation based on recovery milestones:
TB-500: 2–2.5mg 2x/week + BPC-157: 250–500mcg daily (subcutaneous or oral)
TB-500: 2mg 1x/week + BPC-157: 250mcg daily or 5 days on / 2 days off
Discontinue TB-500 when tissue function is restored. BPC-157 can continue at low dose for ongoing gut and joint maintenance.
TB-500 has a favorable safety profile in animal research with minimal reported adverse effects at therapeutic doses. The most commonly reported human side effect is transient fatigue or mild head pressure shortly after injection, typically resolving within hours. There are theoretical concerns about angiogenic peptides in individuals with existing cancer or precancerous lesions — the same VEGF pathway that promotes wound healing also supports tumor vascularity. This is a theoretical risk, not a documented clinical one at research doses, but it warrants awareness.
TB-500 is not approved by the FDA for human use and is classified as a research peptide. It is banned by WADA (World Anti-Doping Agency) for competitive athletes. It is legally purchasable in the United States as a research chemical for non-human research purposes. This legal framework applies to all peptides discussed on this site.
The newsletter covers peptide cycling, GLP-1 optimization, and real-world protocols every week. Or ask Daniel your specific question directly.
Get the Newsletter Ask a QuestionSee how TB-500 fits into the complete protocol in the Peptide Stack guide. Read the companion BPC-157 deep dive for the full injury recovery stack picture. For longevity-focused peptide work, see the Epithalon guide.